ASTA: Financial structure improves via capital increase, but losses persist

Raised 10.45 billion won through 1.2 million new shares (third-party allotment) in Q1 2026; capital stock increased to 8.19 billion won
Fully redeemed convertible bonds of 3 billion won (March 20, 2026); derivative liabilities eliminated, reducing financial risk
Debt-to-equity ratio plummeted from 67.93% to 21.37% (capital expansion effect)
Q1 sales: 464 million won (slight increase from 412 million won in prior year period)
Operating loss: 1.12 billion won; net loss: 1.50 billion won (continued losses)
R&D expenses: 340 million won (73% of sales, high level)
Cash and cash equivalents: 14.92 billion won (surge from 2.91 billion won at end of 2025)
Largest shareholder Cho Eung-joon entered into share pledge agreement with SD Biosensor (related to stock transfer agreement involving change of control)
Saudi joint venture (Company ASTA For Manufacturing) infrastructure construction ongoing

ADVERTISEMENT (250px+)